NEW YORK, March 5, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ:
NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ:
BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth
members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
Ariad Pharmaceuticals Inc. Analyst
Notes
On February 21, 2014, Ariad
Pharmaceuticals, Inc. (Ariad) announced that Alexander J. Denner, Ph.D. has been appointed to
a two-year term on the Company's Board of Directors, effective
immediately. The Company informed that he serves as the chief
investment officer and founding partner of Sarissa Capital
Management LP. Ariad stated that with the addition of Alexander J. Denner, Board of the Company now
includes nine directors, including eight independent directors. The
Company added that it will also appoint another independent
director to the Board, to be selected by the Board and be subject
to Dr. Denner's concurrence. Harvey J.
Berger, M.D., Chairman and CEO of ARIAD, commented, "We
welcome Dr. Denner to the Company's Board and look forward to
working with him to continue building shareholder value, which we
all believe is best achieved through successful commercialization
of Iclusig® (ponatinib), as well as the ongoing development of our
strong pipeline of important cancer medicines." The full analyst
notes on Ariad Pharmaceuticals Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/03052014/ARIA/report.pdf
--
Novavax, Inc. Analyst Notes
On February 27, 2014, Novavax,
Inc. (Novavax) announced that a contract modification has been
executed to extend the base period of performance of its current
contract with the U.S. Department of Health and Human Services,
Biomedical Advanced Research and Development Authority (BARDA) for
the advanced development of Novavax' recombinant seasonal and
pandemic influenza vaccines. Commenting on the extension,
Stanley C. Erck, the Company's CEO
and President said, "While our original development plans
anticipated utilizing the full amount of the contracted base-period
funding within the three-year period, certain scope changes and
development efforts resulted in delayed development timelines.
Extending the base period allows us to continue to access the
remaining base period budget as we initiate a pandemic H7N9 Phase 2
study early this year and prepare for additional Phase 2 and Phase
3 influenza clinical trials, which we expect would occur during the
contract's option period." The full analyst notes on Novavax, Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/03052014/NVAX/report.pdf
--
Fonar Corp. Analyst Notes
On February 27, 2014, Fonar
Corp.'s (Fonar) stock increased 13.16% to end the day at
$24.68 compared to the previous day's
closing price of $21.81. The
Company's stock increased 13.84% over the past three trading days,
compared to the Nasdaq Composite, which rose 0.60% during the same
trading period. The full analyst notes on Fonar Corp. are available
to download free of charge at:
http://www.AnalystsReview.com/03052014/FONR/report.pdf
--
bluebird bio, Inc. Analyst Notes
On February 26, 2014, bluebird
bio, Inc. (bluebird) announced that the Company's management will
be presenting at the Cowen and Company 34th Annual
Health Care Conference to be held on March 2
to 5, 2014 at the Boston Marriott Copley Place Hotel,
Boston, Massachusetts . The
Company said that Nick Leschly,
Chief bluebird, will provide an overview of the Company at the
conference on March 4, 2014, Tuesday
at 8:00 a.m. ET. bluebird added that
simultaneous webcast of Mr. Leschly's overview can be accessed via
"Calendar of Events" section on the Investor and Media page of the
Company website, where a replay will also be available for ninety
days following the conference. The full analyst notes on bluebird
bio, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/BLUE/report.pdf
--
Cara Therapeutics Inc. Analyst
Notes
On February 5, 2014, Cara
Therapeutics Inc. (Cara) announced the closing of its initial
public offering of 5,750,000 shares of common stock at a public
offering price of $11.00 per share,
including the full exercise by the underwriters of their option to
purchase up to 750,000 additional shares of common stock at the
same price to cover over-allotments. The Company stated that the
net proceeds to Cara from the initial public offering were
c.$55.9 million including the sale of
the additional shares from the option and after deducting
underwriting discounts and commissions and estimated offering
expenses. The full analyst notes on Cara Therapeutics Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03052014/CARA/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review